• Effect on functional beta-cell mass as determined by change in ß-cell secretory capacity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  

• Change in acute insulin response to arginine [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Change in glucose-potentiation slope [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Change in insulin sensitivity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Change in disposition index [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Change in PG 50 (the plasma glucose level at which half-maximal insulin secretion is achieved during the glucose-potentiated arginine test) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  

The incidence of type 2 diabetes T2D has reached epidemic proportions throughout the world. In the United States more than 1.5 million new cases of diabetes were diagnosed in 2005, and the estimated prevalence of the disease was over 20 million. Another 54 million Americans are believed to have impaired fasting glucose, which represents a "pre-diabetic" state at increased risk for progression to overt diabetes. T2D ultimately results from an inadequate mass of functional beta-cells, where insufficient beta-cell compensation for insulin resistance leads to the development of impaired glucose tolerance and eventually diabetes. Autopsy studies have demonstrated a decreased beta-cell mass occurring with fasting glucose > 110 mg/dl, consistent with functional studies that demonstrate decreased beta-cell (insulin) secretory capacity beginning in the range of impaired fasting glucose. Strategies that might preserve or expand functional beta-cell mass in vivo would be expected to reverse the progressive deterioration in blood glucose control seen with diabetes. One such strategy involves the incretin hormone glucagon-like peptide-1 (GLP-1), which is trophic for islet beta-cells, having both pro-proliferative and anti-apoptotic effects. However, it is not known whether increasing GLP-1 effects can preserve or enhance functional beta-cell mass in humans. This proposal will determine the effect of increasing GLP-1 levels on functional beta-cell mass in human subjects with impaired fasting glucose (fasting glucose 110 - 126 mg/dl) or early T2D (fasting glucose 127 - 149 mg/dl) where a critical window exists for reversing further beta-cell deterioration. GLP-1 effects will be promoted by administration of either the GLP-1 analog, exenatide, or by increasing endogenous GLP-1 levels through administration of the oral DPP4 inhibitor sitagliptin for a 6-month period. To control for the effect of exenatide and sitagliptin on normalization of blood glucose, subjects will be randomized to receive exenatide, sitagliptin or the sulfonylurea glimepiride, the latter being a first-line anti-diabetogenic agent that will serve as an active comparator.